Cargando…

Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate‐to‐severe plaque psoriasis

This study evaluated the pharmacokinetics (PK), efficacy, safety, and tolerability of bleselumab – a fully‐human anti‐CD40 monoclonal recombinant IgG4. Patients with moderate‐to‐severe psoriasis were randomized on day 1 to receive bleselumab or placebo on days 1, 15 and 29 in a dose‐escalation of bl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anil Kumar, Mysore S., Papp, Kim, Tainaka, Ryo, Valluri, Udaya, Wang, Xuegong, Zhu, Tong, Schwabe, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032846/ https://www.ncbi.nlm.nih.gov/pubmed/29679478 http://dx.doi.org/10.1002/bdd.2130

Ejemplares similares

Effects of ASKP1240 Combined With Tacrolimus or Mycophenolate Mofetil on Renal Allograft Survival in Cynomolgus Monkeys
por: Song, Lijun, et al.
Publicado: (2014)

Pharmacokinetics and Pharmacodynamics of ASKP1240, a Fully Human Anti-CD40 Antibody, in Normal and Renal Transplanted Cynomolgus Monkeys
por: Ma, Anlun, et al.
Publicado: (2014)

Characterization of ASKP1240, a Fully Human Antibody Targeting Human CD40 With Potent Immunosuppressive Effects
por: Okimura, K, et al.
Publicado: (2014)

Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
por: Timmermann, Stine, et al.
Publicado: (2019)

The safety of etanercept for the treatment of plaque psoriasis
por: Papp, Kim A
Publicado: (2007)

P1240: MICROBIOME DIVERSITY IN PATIENTS WITH LYMPHOMA
por: Dlouha, Lucie, et al.
Publicado: (2023)

Population pharmacokinetic and exposure–efficacy analysis of ixekizumab in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)
por: Jackson, Kimberley, et al.
Publicado: (2021)

A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti‐CD40 monoclonal antibody, in kidney transplantation
por: Vincenti, Flavio, et al.
Publicado: (2019)

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
por: Khatri, Amit, et al.
Publicado: (2019)

PReS13-SPK-1240: New aspects on APS pathogenesis
por: Meroni, PL
Publicado: (2013)

Correction to Lancet Infect Dis 2020; 20: 1240–41
Publicado: (2020)

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis
por: Gordon, K.B., et al.
Publicado: (2021)

Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
por: Chan, Wai Sze Agnes, et al.
Publicado: (2022)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

1240. Perceptions of Antimicrobial Stewardship and Antibiotic Use by Healthcare Workers in Latin America
por: Fabre, Valeria, et al.
Publicado: (2023)

Moderate and severe plaque psoriasis: cost-of-illness study in Italy
por: Colombo, GL, et al.
Publicado: (2008)

The experience of pain and redness in patients with moderate to severe plaque psoriasis
por: Martin, Mona L., et al.
Publicado: (2015)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Ren, Vicky, et al.
Publicado: (2013)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Sekhon, Sahil, et al.
Publicado: (2017)

Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil
por: Lopes, Nilcéia, et al.
Publicado: (2019)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
por: Light, Jeremy G, et al.
Publicado: (2021)

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2021)

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
por: Odnopozova, Liudmila, et al.
Publicado: (2022)

Therapeutic Inertia in the Management of Moderate-to-Severe Plaque Psoriasis in Adolescents
por: MELIN, Audrey, et al.
Publicado: (2021)

Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis
por: Jin, Joy Q, et al.
Publicado: (2023)

Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis
por: Hendrix, Nathaniel, et al.
Publicado: (2018)

Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data
por: Papp, Kim A., et al.
Publicado: (2022)

1240. Antibiotic Prescribing in US Nursing Homes Using National Pharmacy Transaction Data
por: Palms, Danielle, et al.
Publicado: (2018)

Abstract: 12.40 In Situ Adipose Tissue Engineering With Oleic Acid Loaded Biospheres
por: Berndt, Sarah, et al.
Publicado: (2017)

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis
por: Tan, H, et al.
Publicado: (2013)

Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis
por: Li, Qian, et al.
Publicado: (2022)

Phase I randomized study of KHK4083, an anti‐OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis
por: Papp, K.A., et al.
Publicado: (2017)

Real‐world, long‐term treatment patterns of commonly used biologics in Canadian patients with moderate‐to‐severe chronic plaque psoriasis
por: Gooderham, Melinda J., et al.
Publicado: (2021)

Novel topical therapy for mild-to-moderate plaque psoriasis: focus on calcitriol
por: Kowalzick, Lutz
Publicado: (2009)

Polymorphisms Associated with Age at Onset in Patients with Moderate-to-Severe Plaque Psoriasis
por: Prieto-Pérez, Rocío, et al.
Publicado: (2015)

Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
por: Malakouti, Mona, et al.
Publicado: (2016)

Gaps in moderate plaque psoriasis management: A survey of Saudi dermatologists
por: Almohideb, Mohammad, et al.
Publicado: (2021)

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
por: Burlando, Martina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_radplsamg2v696906kfnat1kjs